RecruitingCirrhosisAscites Hepatic
Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A small, pilot proof-of-concept placebo-controlled trial to explore the effects of albumin on diuresis in patients with cirrhosis, ascites and lower extremity edema. We will additionally investigate albumin's effect on preventing neurohumoral activation, and acute kidney injury after diuresis.
Sponsor: Anahita Rabiee MD MHS
You may qualify if…
- ✓ Outpatient patients with decompensated cirrhosis with past or current ascites and persistent lower extremity edema despite oral diuretic titration
- ✓ Serum albumin of \< 3.5 g/dL
- ✓ Age \>=18 years old
You may not qualify if…
- ✕ Patients with GFR \< 30mL/min/1.73 m2
- ✕ Changes in oral diuretic regimen in the past 7 days (\*\*patients can enter the study after 7 days of the change)
- ✕ Large Volume paracentesis (LVP) in the past 7 days (\*\*patients can enter the study after 7 days)
- ✕ Albumin infusion within the previous 14 days (\*\* patients can enter the study after 14 days)
- ✕ Spontaneous Bacterial Peritonitis in the past month
- ✕ Active variceal bleeding
- ✕ Current Hepatic encephalopathy (\>= Grade 2 based on West Haven criteria)
- ✕ Co-administration of other diuretics such as Hydrochlorothiazide (amiloride or eplerenone in place of spironolactone, and Bumex/Torsemide in place of furosemide are acceptable)
Where it's recruiting
Connecticut
West Haven
Source: ClinicalTrials.gov · NCT06812390 · last updated 2025-03-11